AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10196655 — intervention group
Group type: COMPARATOR
Intervention: Plain swabs (Control)
Number of subjects: 204
Study 7772456 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS-prevention workshop
Number of subjects: 62
Study 7772456 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 2323135 — intervention group
Group type: EXPERIMENTAL
Intervention: Free patellar tendon autograft
Number of subjects: 19
Study 527352 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg penbutolol twice daily
Number of subjects: 10
Study 527352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30680400 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlicin Capsules 1/time, 3 times/d combined with Kangfuxin liquid 10 mL gargle 3 times/d
Number of subjects: 204
Study 30680400 — intervention group
Group type: COMPARATOR
Intervention: Kangfuxin liquid 10 mL gargle 3 times/d
Number of subjects: 204
Study 30680400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 204
Study 30680400 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlicin Capsules combined with Kangfuxin liquid
Number of subjects: 204
Study 26626861 — intervention group
Group type: EXPERIMENTAL
Intervention: Video glasses
Number of subjects: 83
Study 26626861 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video glasses)
Number of subjects: 83
Study 24928338 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI)
Number of subjects: 347
Study 24928338 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (SAL)
Number of subjects: 347
Study 24928338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 23121378 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg daily)
Number of subjects: 8561
Study 23121378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8561
Study 20445361 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb(mass) measurement using the optimized carbon monoxide rebreathing method
Number of subjects: 11
Study 18759524 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral metronidazole
Number of subjects: 311
Study 18759524 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metronidazole)
Number of subjects: 311
Study 16784013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) and amphotericin B
Number of subjects: 115
Study 16784013 — intervention group
Group type: COMPARATOR
Intervention: Lysine acetylsalicylate (LAS)
Number of subjects: 115
Study 14665524 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (HI) [above the LT]
Number of subjects: 18
Study 14665524 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (MOD) [below the LT]
Number of subjects: 18
Study 14665524 — intervention group
Group type: COMPARATOR
Intervention: No exercise training (CON)
Number of subjects: 18
Study 14665524 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (HI)
Number of subjects: 18
Study 14665524 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (MOD)
Number of subjects: 18
Study 14665524 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (HI) and Moderate-intensity exercise training (MOD)
Number of subjects: 18
Study 10973534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly hypothermic CPB (32 degrees C)
Number of subjects: 144
Study 10973534 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic CPB (37 degrees C)
Number of subjects: 144
Study 10973534 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 144
Study 8776693 — intervention group
Group type: EXPERIMENTAL
Intervention: Portacaval anastomosis (n = 20)
Number of subjects: 44
Study 8776693 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical therapy (n = 24)
Number of subjects: 44
Study 1531004 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (1980-1986) - 36 patients
Number of subjects: 73
Study 1531004 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (1987-Oct. 1990) - 37 patients
Number of subjects: 73
Study 6333298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase followed by heparin
Number of subjects: 250
Study 6333298 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with heparin
Number of subjects: 250
Study 31131359 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAP)
Number of subjects: 1057
Study 31131359 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OP)
Number of subjects: 1057
Study 31131359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LAP and OP
Number of subjects: 1057
Study 29066131 — intervention group
Group type: EXPERIMENTAL
Intervention: TdaP(PTgen/FHA)
Number of subjects: 450
Study 29066131 — intervention group
Group type: COMPARATOR
Intervention: Tdap (comparator)
Number of subjects: 450
Study 29066131 — intervention group
Group type: EXPERIMENTAL
Intervention: aP(PTgen/FHA)
Number of subjects: 450
Study 27246726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab alone
Number of subjects: 0
Study 27246726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with irinotecan
Number of subjects: 0
Study 27246726 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab alone or with irinotecan
Number of subjects: 0
Study 25154829 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Rituximab (MR)
Number of subjects: 289
Study 25154829 — intervention group
Group type: COMPARATOR
Intervention: Re-treatment Rituximab (RR)
Number of subjects: 289
Study 25154829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (RR and MR)
Number of subjects: 289
Study 22525771 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g of glucose (Glu)
Number of subjects: 9
Study 22525771 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g of galactose (Gal)
Number of subjects: 9
Study 22525771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 20488452 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparing symbols group (instruction involving comparing the equal sign with greater than and less than symbols)
Number of subjects: 0
Study 20488452 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal sign group (instruction about the equal sign only)
Number of subjects: 0
Study 20488452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific instruction mentioned)
Number of subjects: 0
Study 20488452 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparing symbols group
Number of subjects: 0
Study 17851937 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlaryngoscopy (MLS)
Number of subjects: 43
Study 17851937 — intervention group
Group type: COMPARATOR
Intervention: Septoplasty
Number of subjects: 43
Study 16225492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate 100 mg twice a day
Number of subjects: 41
Study 16225492 — intervention group
Group type: COMPARATOR
Intervention: Iron-polymaltose complex 200 mg once a day
Number of subjects: 41
Study 16225492 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of treatments
Number of subjects: 41
Study 16225492 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 41
Study 12419719 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.1 mg*kg(‐1) orally 60 min preoperatively (Group I)
Number of subjects: 61
Study 12419719 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.1 mg*kg(‐1) orally 90 min preoperatively (Group II)
Number of subjects: 61
Study 12419719 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group III)
Number of subjects: 61
Study 10365010 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.25% w/v 50 ml)
Number of subjects: 66
Study 10365010 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (0.25% w/v 50 ml)
Number of subjects: 66
Study 10365010 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 66
Study 10365010 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 66
Study 7574352 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (5 ml containing 500 IU of thrombin) applied by spray in the area of axillary dissection
Number of subjects: 40
Study 7574352 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 40
Study 7574352 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (group A)
Number of subjects: 40
Study 7574352 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 40
Study 7574352 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 2340347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of vincamine
Number of subjects: 0
Study 2340347 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal absorption of vincamine dissolved in saliva
Number of subjects: 0
Study 7029650 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms/d of 15(R)‐15‐methyl prostaglandin E2 (MPGE2) for one month
Number of subjects: 13
Study 7029650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30833160 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles-rubella plus LJEV group
Number of subjects: 1093
Study 30833160 — intervention group
Group type: COMPARATOR
Intervention: Measles-rubella group
Number of subjects: 1093
Study 27807037 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie deprivation (266 ± 61 kcal/d)
Number of subjects: 23
Study 27807037 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie deprivation with aerobic exercise (4 h/d at 40-65% peak VO2)
Number of subjects: 23
Study 27228204 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-related factors including child anthropometry, breastfeeding and complementary feeding frequencies, dietary diversity, egg and oil intake, and reduced infectious disease morbidities
Number of subjects: 583
Study 27228204 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in length-for-age Z score
Number of subjects: 583
Study 25480991 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation zotarolimus-eluting stent (R-ZES) in bifurcation lesions
Number of subjects: 3475
Study 25480991 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation zotarolimus-eluting stent (R-ZES) in non-bifurcation lesions
Number of subjects: 3475
Study 25480991 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation zotarolimus-eluting stent (R-ZES) in bifurcation lesions (first 30 days)
Number of subjects: 3475
Study 25480991 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation zotarolimus-eluting stent (R-ZES) in non-bifurcation lesions (first 30 days)
Number of subjects: 3475
Study 25480991 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation zotarolimus-eluting stent (R-ZES) in bifurcation lesions (31 days to 3 years)
Number of subjects: 3475
Study 25480991 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation zotarolimus-eluting stent (R-ZES) in non-bifurcation lesions (31 days to 3 years)
Number of subjects: 3475
Study 22470104 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine lozenge (NL)
Number of subjects: 27
Study 22470104 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge (PL)
Number of subjects: 27
Study 22470104 — intervention group
Group type: EXPERIMENTAL
Intervention: DT cigarette administration
Number of subjects: 27
Study 21059743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 μg/kg
Number of subjects: 12
Study 21059743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 12
Study 17641872 — intervention group
Group type: EXPERIMENTAL
Intervention: Total elbow arthroplasty using semiconstrained GSB III elbow replacement prostheses
Number of subjects: 177
Study 17641872 — intervention group
Group type: EXPERIMENTAL
Intervention: Total elbow arthroplasty using semiconstrained Coonrad‐Morrey prostheses
Number of subjects: 177
Study 17641872 — intervention group
Group type: EXPERIMENTAL
Intervention: Total elbow arthroplasty using Souter‐Strathclyde unconstrained, unlinked prosthesis
Number of subjects: 177
Study 17641872 — intervention group
Group type: EXPERIMENTAL
Intervention: Total elbow arthroplasty using constrained link hinge prostheses
Number of subjects: 177
Study 17641872 — intervention group
Group type: EXPERIMENTAL
Intervention: Total elbow arthroplasty using custom‐made prostheses
Number of subjects: 177
Study 17641872 — intervention group
Group type: EXPERIMENTAL
Intervention: Total elbow arthroplasty using Pritchard elbow replacement
Number of subjects: 177
Study 17641872 — intervention group
Group type: EXPERIMENTAL
Intervention: Total elbow replacement (all types)
Number of subjects: 177
Study 16336366 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-aid booklet given at 28 weeks' gestation
Number of subjects: 227
Study 16336366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision-aid)
Number of subjects: 227
Study 11886900 — intervention group
Group type: EXPERIMENTAL
Intervention: Three applications of 1000 impulses of low-energy shock waves (Group I)
Number of subjects: 112
Study 11886900 — intervention group
Group type: COMPARATOR
Intervention: Three applications of ten impulses of low-energy shock waves (Group II)
Number of subjects: 112
Study 10634020 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with controlled ventilation (Group 1)
Number of subjects: 60
Study 10634020 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA) with spontaneous breathing (Group 2)
Number of subjects: 60
Study 10182206 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher characteristics and program fidelity
Number of subjects: 0
Study 10182206 — intervention group
Group type: COMPARATOR
Intervention: Teacher characteristics
Number of subjects: 0
Study 1820294 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg b.i.d.)
Number of subjects: 170
Study 1820294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 7044655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-aspirin/dipyridamole combination (990 mg/day aspirin and 225 mg/day dipyridamole)
Number of subjects: 27
Study 7044655 — intervention group
Group type: COMPARATOR
Intervention: Low-dose-aspirin/dipyridamole (330 mg/day aspirin and 225 mg/day dipyridamole)
Number of subjects: 27
Study 7044655 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (990 mg/day)
Number of subjects: 27
Study 31714123 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological resilience measures
Number of subjects: 748
Study 29720876 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery training
Number of subjects: 30
Study 29720876 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 30
Study 29720876 — intervention group
Group type: COMPARATOR
Intervention: Control group (mentally stimulating games)
Number of subjects: 30
Study 26364263 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg) immediately
Number of subjects: 544
Study 24333493 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10-mg once-daily maintenance dose (with or without a 60-mg loading dose)
Number of subjects: 110
Study 24333493 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (combined groups)
Number of subjects: 110
Study 24333493 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor (continued therapy)
Number of subjects: 110
Study 22315052 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel care pathway including diagnosis of 'diseased' QoL and up to five standardised treatments for specific QoL defects
Number of subjects: 200
Study 22315052 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care adhering to the German national guideline for breast cancer
Number of subjects: 200
Study 18571336 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D radiation therapy (n = 29)
Number of subjects: 67
Study 18571336 — intervention group
Group type: COMPARATOR
Intervention: 2D radiation therapy (n = 38)
Number of subjects: 67
Study 17467138 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam autoclaving (121 degrees C, 5min)
Number of subjects: 20
Study 17467138 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion in 0.1% (w/v) thymol-distilled water solution (24h)
Number of subjects: 20
Study 17467138 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma irradiation (4100Gy)
Number of subjects: 20
Study 17467138 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 15965572 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 15965572 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 15965572 — intervention group
Group type: EXPERIMENTAL
Intervention: Device therapies
Number of subjects: 0
Study 15965572 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol or Metoprolol
Number of subjects: 0
Study 11948036 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity, lower-extremity endurance program
Number of subjects: 40
Study 11948036 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity, multicomponent calisthenics program
Number of subjects: 40
Study 11948036 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 11512042 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drinks
Number of subjects: 0
Study 9663818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (slide show, weekly phone calls, calendar)
Number of subjects: 45
Study 9663818 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 45
Study 7512292 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 74
Study 7512292 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 74
Study 3042309 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% mixed-carbohydrate diet
Number of subjects: 5
Study 3042309 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% mixed-carbohydrate diet
Number of subjects: 5
Study 3042309 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast meal (60% carbohydrate diet)
Number of subjects: 5
Study 3042309 — intervention group
Group type: EXPERIMENTAL
Intervention: Big Mac meal (43% carbohydrate)
Number of subjects: 5
Study 3042309 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast meal (40% carbohydrate diet)
Number of subjects: 5
Study 7937285 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg twice/day
Number of subjects: 10
Study 7937285 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine alone
Number of subjects: 10
Study 7937285 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 10
Study 356754 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside (Vidarabine)
Number of subjects: 50
Study 356754 — intervention group
Group type: COMPARATOR
Intervention: Idoxuridine (IDU)
Number of subjects: 50
Study 31817731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 0
Study 29045554 — intervention group
Group type: EXPERIMENTAL
Intervention: VCP (veliparib with carboplatin/paclitaxel)
Number of subjects: 290
Study 29045554 — intervention group
Group type: EXPERIMENTAL
Intervention: VT (veliparib with temozolomide)
Number of subjects: 290
Study 29045554 — intervention group
Group type: COMPARATOR
Intervention: PCP (placebo with carboplatin/paclitaxel)
Number of subjects: 290
Study 26578074 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day trimethoprim-sulfamethoxazole therapy
Number of subjects: 249
Study 26578074 — intervention group
Group type: COMPARATOR
Intervention: 10-day trimethoprim-sulfamethoxazole therapy
Number of subjects: 249
Study 24676964 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAP plus treatment as usual (TAU)
Number of subjects: 221
Study 24676964 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 221
Study 22964805 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 160
Study 22964805 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 160
Study 21128814 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily)
Number of subjects: 3449
Study 21128814 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin plus vitamin K antagonist
Number of subjects: 3449
Study 21128814 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily)
Number of subjects: 3449
Study 21128814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3449
Study 21128814 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3449
Study 17504795 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (H-IMT), 3 times a week for 8 weeks
Number of subjects: 33
Study 17504795 — intervention group
Group type: COMPARATOR
Intervention: Sham inspiratory muscle training (S-IMT), 3 times a week for 8 weeks
Number of subjects: 33
Study 16321744 — intervention group
Group type: EXPERIMENTAL
Intervention: Perilesional fat-sparing ring observed in malignant lesions
Number of subjects: 132
Study 16321744 — intervention group
Group type: EXPERIMENTAL
Intervention: Perilesional fat-sparing ring observed in benign lesions
Number of subjects: 132
Study 16321744 — intervention group
Group type: COMPARATOR
Intervention: Presence of fat-sparing ring related to lesion size
Number of subjects: 132
Study 16321744 — intervention group
Group type: COMPARATOR
Intervention: Presence of fat-sparing ring related to lesion type
Number of subjects: 132
Study 16321744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-sparing rings in metastases
Number of subjects: 132
Study 16321744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-sparing rings in primary malignant tumors
Number of subjects: 132
Study 16321744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-sparing rings in hemangiomas
Number of subjects: 132